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Background. Cardiovascular diseases and chronic obstructive pulmonary disease (COPD) are both associated with abdom-
inal aortic aneurysms (AAA). The aim of this study was therefore to analyse whether screening for AAA could be restricted
to men with such diseases (high risk group).
Methods. Before the date of randomisation of a population screening trial of 12,639 64e73-year-old males, all discharge
diagnoses from the National Patient Registry concerning AAA-related diseases were merged with the screening results on
attendance, AAA prevalence, and AAA-related mortality and overall mortality. Differences in proportions were compared
by Chi square tests and differences in mortality by Cox regression analyses.
Results. The attendance rate was 78.8% and 6.7% had an AAA in the high risk group compared to 75.8% attendance
(P< 0.001) and 2.9% (P< 0.001) in the remaining population. Cumulatively, screening of only high risk men with would
have required 72.9% (95% C.I.: 72.3e74.5%) fewer screening invitations, would have discovered 46.1% (95% C.I.: 38.9e
53.4%) of the AAA cases diagnosed and prevented 46.7% (95% C.I.: 28.3e65.7%) of the AAA-related deaths. However,
screening decreased AAA-related mortality both among men with and without known COPD or cardiovascular diseases:
mortality ratio: 0.22 (95% C.I.: 0.08e0.65), P¼ 0.006, and 0.24 (95% C.I: 0.09e0.63, P¼ 0.004, respectively.
Conclusion. High-risk population screening would prevent less than half of AAA-related deaths. Therefore, restricting
screening to such high-risk groups does not seem justified, but cost effectiveness analyses are needed to reach a firm
conclusion.
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Abdominal aortic aneurysms (AAA) seldom cause
symptoms before rupture. Ultrasonographic screen-
ing is safe, valid and cheap, so it seems to be an ideal
method for AAA screening.1
In 1987, a group of screening experts worked for the
Council of Europe, evaluating the 1968 WHO screen-
ing criteria.2 The criteria were expanded and new cri-
teria were formulated.3 One of the new criteria was
that ‘‘the screening test must be acceptable to the pop-
ulation to be screened’’. They explained the meaning of
this: ‘‘this means not only a sufficient overall take-up,
but also a sufficient take-up-rate for high risk’’.3
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chronic obstructive pulmonary disease (COPD),6 pe-
ripheral arterial occlusive disease,7e9 angina pectoris,
stroke or transient cerebral ischemia10 are associated
with AAA, and we have previously shown that pa-
tients with these other disorders attend population
screening for AAA more frequently than those without
such diseases.10 However, sufficient attendance is not
enough if the treatment is unacceptable for high-risk
patients due to contraindications for surgery, or the ad-
verse effects of the treatment outweigh the benefits for
high risk patients. This could leave a large proportion
of untreated men at high risk of aneurysm rupture,11
and those offered operation would have increased
risk of postoperative complications and deaths.12 In
all, the benefit of screening of a high risk group could
be limited. On the other hand, the association between
AAA and these diseases makes it possible that AAA
screening could be restricted to such men.rved.
54 J. S. Lindholt et al.The aims of this study were to perform a stratified
analysis in a randomised population screening trial
for AAA in men, with or without hospital diagnoses
of COPD or cardiovascular disease, using the outcome
measures of attendance, AAA prevalence, AAA-
specific mortality and overall mortality.
Patients and Methods
In 1994 all men in Viborg County in Denmark born in
1921e1929 were randomised either to a to be offered
an abdominal ultrasonographic scan at their regional
hospital or to a control group without a scan. FromEur J Vasc Endovasc Surg Vol 34, July 20071995 to 1998, all men were recruited and randomised
the year they turned 65 years. Controls were not in-
formed about the trial. Randomisation produced
6306 controls and 6333 were invited for screening.13
The invitation letter explained the trial and atten-
dance was taken as consent of participation. The
B-mode scans were carried out with a small portable
Phillips SDR 1550 with a linear 4-mHz transducer
and calliper light pen. An AAA was defined as an in-
frarenal aortic diameter of 30 mm or more. Patients
with an AAA of 3e4.9 cm were offered follow-up
examination, while patients with an AAA of 5 cm or
more were referred to vascular evaluation for possible
surgery.Table 1. Definitions of six high-risk groups of AAA due to classification of previous hospital submissions due to AAA-related diseases
according to the 8th and 10th WHO classifications of diseases
Diseases associated with AAA Included WHO
classification codes
Included WHO classification diagnoses
Arterial Hypertension (Hyp. Art.) 400.00-400.99 Hypertensio arterialis maligna
401.99 Hypertensio arterialis essentialis benigna
402-4.99 Mb. Cordis/Renalis hypertensivus
410.09 Infarctus myocardii acutus cum hyp.art.
41.109 Mb. Cordis arterioscleroticus et subacutus alius cum hyp.art.
412-3.09 Mb. Cordis Arterioscleroticus/Asymptomaticus cum hyp.art.
430.00-09 Haemorrhagia subarachnidalis cum hyp.art.
431.00þ09 Haemorrhagia intracerebralis/cerebri cum hyp. art.
433-4.09 Thrombosis/Embolia cerebri cum hyp. art.
435.09 Ischaemia cerebri transitoria cum hyp. art.
436.00-09 Mb. Cordis Cereborvascularis male definitus cum hyp. art.
437.00-09 Mb. Cerebrovascularis ischaemicus generalisatus cum hyp. art.
I10-I15 Hypertensio arterialis
AMI1 410.09þ99 Infarctus myocardii acutus cum/sive hyp.art.
I21-I23 Infarctus myocardii acutus/Infarctus myocardii acutus recidivans
Angina Pectoris 411.09þ99 Mb. Cordis arterioscleroticus et subacutus alius cum/sive hyp.art.
413.09þ99 Angina Pectoris cum/sive Hyp.Art.
I20 Angina Pectoris
COPD2 491.00-493.09 Broncitis Chronica, Emphysema pulm., Astma,
51.700-517.09 Alia pneumonia chronica interstitialis
J40-J47 Broncitis Chronica, Emphysema pulm., Astma, Mb.
Chronicus Pulmonis Obstructivus Alius
POAD3 440.09þ20,30,39 Arteriosclerosis aortae/extremitatis inf./art.iliacae
440.99 Arteriosclerosis universialis et non specificata
444.00,09,19 Embolia/thrombosis bifurcationis aortae/aorta abdominalis
444.41-99 Embolia/thrombosis Art. Femoralis/Art. Popliteae/Art. Tibialis/
Art. Periphericae Extremitatis/Art. Extremitatis alia definita/
Art. Extremitatis/Art. Iliacae/Art. Aliae non specificata
445.00-445.99 Gangraena
I70 (Excl.I70.1) Arteriosclerosis
I74 (Excl.I74.2) Emboliaet thrombosis arteriarum
Stroke el. TIA4 431.00-432.99 Haemorrhagia cerebri/Occlusio et stenosis Art. Precerebralis
433-4.09þ99 Thrombosis/Embolia Cerebri
435.09þ99 Ischaemia cerebri transitoria
436.01þ90þ99 Apoplexia cerebri/Mb. Cerebrovascularis acutus male definitus
I63-I64 Infarctus Cerebri/Apoplexia Cerebri non specificata
I65-I66 Occlusio/Stenosis Art. Precerebralis/Art Cerebri sive infarctu cerebri
I67 Morbi cerebrovascularis alii
1 Acute myocardial infarction.
2 Chronic obstructive pulmonary disease.
3 Peripheral occlusive arterial disease.
4 Transient ischemic attack.
55High- and Low-Risk Screening for AAAAll previous discharge diagnoses recorded in the
National Patient Registry concerning chronic obstruc-
tive pulmonary disease and cardiovascular diseases
including hypertension were ascertained for all en-
rolled men up until the date of enrolment. This regis-
try, established in 1977, records civil registration
number, dates of discharge and up to 20 discharge di-
agnoses a.o. Diagnoses were classified according to
the Danish version of the International Classification
of Diseases (ICD), 8th revision, until the end of 1993,
and according to the 10th revision hereafter.6
Based on previous reports,4e10 six groups were de-
fined as having a high risk of AAA, hypertension, MI,
COPD, other ischaemic heart disease MI, peripheral
occlusive arterial disease affecting the lower limb,
and stroke or transient ischemic attack (Table 1). If
a man was classified into one or more of these groups,
he was considered as being at high risk for having
an AAA (high risk group). A similar procedure was
followed for hospital discharge diagnoses after the
date of randomisation until 31 Dec. 2001.
Deaths were identified in the national Office of
Civil Registration and causes of deaths were identi-
fied in the national Registry of Causes of Death14
from the date of randomisation to 31 Dec. 2001 and
potential AAA-related deaths were identified. The
hospital and autopsy records of deaths coded as
I71.3 (ruptured AAA) or I71.4 (unruptured AAA) as
primary or participating cause of death were re-
viewed by two vascular surgeons, as described previ-
ously.13 Differences in proportions were tested by Chi
square tests. Hazards were used to estimate the AAA-
specific mortality ratio by Cox regression analysis.The proportional hazards assumption was evaluated
graphically. Analyses were performed using SPSS
12.0, Stata 8.0 and PEPI. The survival analyses were
calculated on the basis of ‘‘intention to screen’’ as
from the date of randomisation to death or 31 Dec.
2001.
The trial was approved by the local scientific ethics
committee and reported to the Danish Registry Board.
Results
Among the 6333 men randomized to screening, 4852
attended (76.6%), of whom 4816 had aortas visible
on ultrasonography. Among these, 191 had an AAA
(4.0%) (Table 2).
COPD and other cardiovascular disorders in the
control group were associated with increased risk of
AAA-related death with a mortality ratio of 2.70
(95% C.I.: 1.44e5.07), P¼ 0.002.
The high-risk group
In all, 3355 (27.5% (95% C.I.: 25.8e27.3%)) had had
a previous hospital discharge diagnosis of one or
more relevant co-morbidities before randomisation.
Screening only such high risk men would therefore
require 1681 invitations instead of 6333, correspond-
ing to 72.9% (95% C.I.: 72.3e74.5%) fewer screening
invitations (Tables 2 and 3).
The mean age and follow-up period are shown in
Table 3. There were no significant differences betweenTable 2. Attendance rates and prevalence of abdominal aortic aneurysm in six high risk groups and the remaining population
High-risk
group
Attended (n) Frequency
(Per cent)
Difference between
proportions in per
cent (95% C.I)A
AAA
(n)
Prevalence
(Per cent)
Difference between
proportions in per
cent (95% C.I)B
Hypertension 350 (of 434) 80.1 (76.6e84.3%) 3.8 (0.2e7.8%) 30 8.6 (5.9e12.0%) 5.0 (1.9e8.2%)
AMI1 528 (of 640) 82.5 (79.3e85.3%) 6.6 (3.3e9.8%) 47 8.9 (6.6e11.7%) 5.6 (3.0e8.2%)
COPD2 328 (of 457) 71.8 (67.4e75.9%) 5.2 (0.8e9.6%) 16 4.9 (2.8e7.8%) 1.0 (1.5e3.6%)
IHD3 excl. AMI 501 (of 607) 82.5 (79.3e85.5%) 6.5 (3.2e9.8%) 35 7.0 (4.9e9.6%) 3.4 (1.0e5.8%)
PAD4 134 (of 170) 78.8 (71.9e84.7%) 2.3 (4.3e8.8%) 11 8.2 (4.2e14.2%) 4.4 (0.7e9.4%)
Stroke or TIA5 215 (of 294) 73.1 (67.7e78.1%) 3.7 (1.7e9.0%) 11 5.1 (2.6e9.0%) 1.2 (2.0e4.5%)
All at high risk 1324 (of 1681) 78.8 (76.7e80.7%) 3.0 (0.7e6.1%) 88 6.7 (5.4e8.1%) 3.8 (2.3e5.3%)
All at low risk 3528 (of 4652) 75.8 (74.6e77.1%) e 103 2.9 (2.4e3.5%)
All 4852 (of 6333) 76.6 (75.6e77.7%) e 191 4.0 (3.4e4.5%)
A Third column shows the difference in proportion of attenders to screening in the specific high-risk group using those not included in the
specific high-risk group as reference.
B Sixth column shows the difference in proportion of having an AAA for men in the specific high-risk group using those not included in
the specific high-risk group as reference.
1 Acute myocardial infarction.
2 Chronic obstructive pulmonary disease.
3 Ischemic heart disease.
4 Peripheral occlusive arterial disease.
5 Transient ischemic attack.Eur J Vasc Endovasc Surg Vol 34, July 2007
56 J. S. Lindholt et al.Table 3. Prevalence, age, observation time, AAA-related and total mortality rates per 1000 observation years in six high-risk groups and
remaining risk subjects
High-risk
group
Numbers Proportion in
percent
(95% C.I.)
Age in
years (SD)
Mean obs. time
(years) and
(25e50e75
percentiles)
Total
deaths
(n)
Total
mortality
rate per
1000 years
AAA-related deaths AAA-related
mortality rate
in the control
group per
1000 years
Invited Controls
Hypertension 875 6.92 (6.49e7.38%) 67.9 (2.8) 5.3 (3.3e6.4e7.4) 325 70.1 2 5 2.15
MI1 1284 10.2 (9.64e10.7%) 68.1 (2.9) 5.5 (3.5e6.4e7.4) 463 65.6 0 7 2.03
COPD2 860 6.80 (6.37e7.26%) 68.3 (3.0) 5.2 (3.3e5.4e7.2) 372 83.2 1 7 3.42
IHD3 excl MI 1195 9.46 (8.95e9.98%) 68.0 (2.9) 5.3 (3.3e6.1e7.4) 406 64.1 0 5 1.62
PAD4 339 2.68 (2.40e2.98%) 68.2 (3.1) 5.1 (3.3e5.3e7.2) 157 90.1 1 4 4.62
Stroke or TIA5 616 4.87 (4.51e5.26%) 68.4 (2.9) 5.2 (3.3e6.3e7.4) 267 83.3 1 4 2.34
High risk 3355 26.5 (25.8e27.3%) 68.1 (2.9) 5.4 (3.4e6.4e7.4) 1217 67.2 4 18 1.99
Low risk 9284 73.5 (72.7e74.2%) 67.8 (2.8) 6.1 (5.2e7.2e7.6) 1611 28.4 5 21 0.74
All 12,639 e 67.8 (2.8) 5.9 (4.1e7.2e7.6) 2828 37.9 9 39 1.05
1 Myocardial infarction.
2 Chronic obstructive pulmonary disease.
3 Ischemic heart disease.
4 Peripheral occlusive arterial disease.
5 Transient ischemic attack.
Assessed for eligibility:
Males 64-73 years old,
living in Viborg County
(N=12,639)  Excluded
(N=0) 
Randomised
(N=12,639) 
Randomised to screening offer
(N=6333) 
In high risk:
(N=1681) 
In low risk:
(N=4652)
Randomised to no screening
(N=6306) 
In high risk:
(N=1674) 
In low risk:
(N=4632)
Attended
screening
(N=4852)
Did not attend
screening
 (N=1481)
In high risk:
(N=1324)
In low risk:
(N=3528) 
In high risk:
(N=357)
In low risk:
(N=1124) 
Analyzed
(on intention to treat basis) 
In high risk:
(N=1681)
AAA-deaths: 4
Total deaths: 609  
In low risk:
(N=4652)
AAA-deaths: 5
Total deaths: 767  
Analyzed
(on intention to treat basis) 
In high risk:
(N=1674)
AAA-deaths: 18
Total deaths: 608 
In low risk:
(N=4632)
AAA-deaths: 21
Total deaths: 844
Fig. 1. Flow-chart concerning screening for abdominal aortic aneurysm classified according to pre-existing hospital admis-
sions due to AAA-related disease (high risk) or not (low risk).Eur J Vasc Endovasc Surg Vol 34, July 2007
57High- and Low-Risk Screening for AAAthe invited group and the control group in terms of
age and follow-up.
The screening attendance rate in high risk subjects
was 78.8%. Among these, 88 (6.7%, 95% C.I.: 5.4e
8.1%) had an AAA, compared with 191 in the total
population screening, corresponding to 46% (95%
C.I.: 39e53%) of all the AAAs diagnosed.
Among those with a previous MI, 82.5% attended
and 8.9% (95% C.I.: 6.6e11.7%) had an AAA (Table 3).
In all, 1217 died in the high-risk group. Among
these, 22 died due to AAA: 4 in the invited group
and 18 in the control group (hazard ratio: 0.22 (95%
C.I.: 0.08e0.65), P¼ 0.006, Figs. 1 and 2). ‘‘Overall,
39 died of AAA in the control group and 9 in the in-
vited group (Table 1). Consequently, high risk screen-
ing alone would have prevented 14 of the prevented
30 AAA related deaths observed in the population
screening trial, corresponding to 46.7% (95% C.I.:
28.3e65.7%) of the AAA-related deaths prevented in
the randomised mass screening trial.
The low-risk group
In all, 9284 (73.5% (95% C.I.: 72.7e74.2%)) had no pre-
randomisation discharge diagnosis of one or more
AAA-related diseases, mean age and follow-up are
given in Table 3, and there were no differences between
the invited group and the control group in terms.
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Fig. 2. Kaplan-Meier estimates of mortality from abdominal
aortic aneurysms. Screening group and control group
among high risk men (P¼ 0.006).The attendance and AAA prevalence rates were sig-
nificantly lower than the rates seen in the high-risk
group: 75.8% attended (P< 0.001) and 103 (2.9%,
95% C.I.: 2.4e3.5%) had an AAA (P< 0.001). The dif-
ference in the proportion of attendance and the preva-
lence of AAA between the high- and the low-risk
group was 3.0% (95% C.I.: 0.7e6.1%) and 3.8% (95%
C.I.: 2.3e5.3%), respectively. Overall, 1611 subjects
died, 26 of AAA-related causes: 5 from the invited
group and 21 form the control group (hazard ratio:
0.24 (95% C.I: 0.09e0.63, P¼ 0.004, Fig. 3). Low-risk
screening would have prevented 16 of the 30 pre-
vented AAA deaths in the whole mass screening trial,
corresponding to 53.3% (95% C.I.: 34.3e71.7%).
Discussion
Screening significantly decreased AAA-related
mortality equally in men with and without COPD
and/or other cardiovascular diseases. The pattern,
reported previously, that men at high risk for having
an AAA attended screening more frequently than
men at lower risk was confirmed after additional
recruitment of 65-year-old men in the 4 years after
the initial study.10
Limiting screening to high risk men (with COPD
and/or other cardiovascular diseases) would have
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Fig. 3. Kaplan-Meier estimates of mortality from abdominal
aortic aneurysms. Screening group and control group
among men without known COPD and/or cardiovascular
disease (P¼ 0.004).Eur J Vasc Endovasc Surg Vol 34, July 2007
58 J. S. Lindholt et al.reduced the number screened individuals by 73%, but
at a cost of missing 52% of the AAAs in the overall
population.
The number of outcomes almost doubled the num-
ber in the high-risk group during the observation
period. The target group was men aged 64e73. If
permanent screening was to be introduced, the target
group would probably only include 65-year-old men,
and the proportion of men at high risk would there-
fore be much lower.
For some diagnoses, e.g. hypertension,15 Danish
studies have reported considerable misclassification
bias with only 40e60% of cases registered although
other cardiovascular discharge diagnoses such as MI
and COPD have shown a positive predictive value
both reaching 90%.16,17 Errors in co-morbidity report-
ing and lack of information about smoking habits
biases the results towards the null hypothesis, but it
also allows quick identification of men at high risk. It
would probably have been possible to identify more
high-risk men and consequently to have included
more of the AAA diagnosed in the high-risk group if
we had searched the written hospital and GP records.
However, it would hardly have been worth the effort
because the total time consumption per scan in mass-
screening was less than 10 minutes including invita-
tion, information, scanning and registration.18
The direct costs of a screening scan were £7.48.18
Based upon these costs and the AAA prevalences ob-
served in the high risk and the remaining population
groups, we estimate the detection costs at approx.
£115 for diagnosing an AAA in the high-risk group
and approx. £260 in the low-risk group. This is a small
difference, but direct scanning costs account for less
than 10% of the total screening costs17 and that the
co-morbidities of the high risk group are likely to be
associated with increased postoperative complica-
tions and mortality and reduced long-term survival.
The long-term costs per saved living year therefore
may be increased in the high-risk groups compared
with the low-risk group, but the best proof of this
would be an advanced cost effectiveness analysis.
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